Fig. 2From: Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasisKaplan–Meier plot of progression-free survival (A) and overall survival (B) in the patients treated by gefitinib/erlotinib, afatinib or osimertinibBack to article page